RANI

Rani Therapeutics Holdings, Inc.

• Dow Jones·04/01 21:10

  Rani Therapeutics Is Maintained at Buy by Canaccord Genuity

• Dow Jones·04/01 21:10

  Rani Therapeutics Price Target Cut to $5.00/Share From $9.00 by Canaccord Genuity

• Benzinga·04/01 21:01

  Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

• TipRanks·04/01 14:00

  Analysts Conflicted on These Healthcare Names: Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS)

• TipRanks·04/01 11:31

  Rani Therapeutics price target lowered to $5 from $9 at Canaccord

• Reuters·03/27 23:47

  Rani Therapeutics files initial beneficial ownership statement; Chief Technical Officer Alireza Javadi reports 10,075 Class A shares

• Dow Jones·03/27 11:00

  Rani Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

• Benzinga·03/27 10:50

  HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

• TipRanks·03/27 10:20

  Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Mirum Pharmaceuticals (MIRM) and NovoCure (NVCR)

• Reuters·03/26 20:26

  Rani Therapeutics' net loss narrows in Q4 as costs fall

• Seeking Alpha·03/26 20:23

  Rani Therapeutics GAAP EPS of -$0.07 in-line, revenue of $1.46M misses by $3.54M

• Reuters·03/26 20:11

  Rani Therapeutics FY2025 net loss narrows 27.6% to $41 million; revenue rises 58.9% to $1.6 million

• Dow Jones·03/26 20:11

  *Rani Therapeutics Sees Funding Sufficient Into 4Q27 >RANI

• Dow Jones·03/26 20:11

  *Rani Therapeutics 4Q Loss/Shr 7c >RANI

• Dow Jones·03/26 20:10

  *Rani Therapeutics 4Q Rev $1.5M >RANI